Nurix Therapeutics Inc
(NAS:NRIX)
$
15.95
-0.1 (-0.62%)
Market Cap: 974.03 Mil
Enterprise Value: 767.13 Mil
PE Ratio: 0
PB Ratio: 4.65
GF Score: 68/100 Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023 / 08:35PM GMT
Release Date Price:
$10.01
(+1.83%)
Greg Renza
RBC Capital Markets - Analyst
Welcome back, everyone, to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotech equity research analysts here at RBC. And we're pleased to have Nurix Therapeutics today. And joining us from the company is the President and CEO, Arthur Sands. Arthur?
Arthur Sands
Nurix Therapeutics, Inc. - President, CEO & Board Director
Thanks, Greg. Thanks for having us.
Greg Renza
RBC Capital Markets - Analyst
Good to see you. Let's dive right in. For those maybe less familiar with the Nurix story, just have you give a brief overview of Nurix, the targeted protein modulation technology and platform?
Arthur Sands
Nurix Therapeutics, Inc. - President, CEO & Board Director
Yes. So we have a new approach at Nurix which involves discovery of small molecules that can change protein levels or modulate protein levels within the cell in a very specific way. So we achieved this by harnessing the ubiquitin
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot